TGA seeks ban on branded painkiller marketing tactics

The recommendation is contained in a consultation paper published by the regulator yesterday, following a major review of packaging and labelling.

The wide-ranging measures are designed to make labels clearer and more uniform to avoid confusion among prescribing doctors, pharmacists and patients.

It proposes medicines that contain the same quantity of active ingredient not be “selectively differentiated or marketed for a subset of symptoms or uses, unless the medicine has specific characteristics that make it more suitable